This is an old revision of this page, as edited by JCW-CleanerBot(talk | contribs) at 01:49, 17 July 2022(task, replaced: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie → Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 01:49, 17 July 2022 by JCW-CleanerBot(talk | contribs)(task, replaced: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie → Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie)
Ro48-8684 is a water-soluble benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s, which was designed along with Ro48-6791 as an improved replacement for midazolam, but ultimately proved to have little advantages over the parent drug and has not been introduced into clinical practice.[1][2]
^Albrecht S, Hering W, Ihmsen H, Schwilden H, Schüttler J (October 1999). "[Pharmacokinetic-pharmacodynamic modeling in phase II of drug development. A comparative study with young and old volunteers with benzdiazepine as an example]". Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 34 (10): 634–7. doi:10.1055/s-1999-213. PMID10548960.